Risk factor
Low price volatility
Profitability factor
Weak margins and returns
About
Koninklijke Philips N.V. (PHG) functions as a prominent health technology enterprise, with its operations spanning across North America and numerous international markets. The company's diverse activities are organized into three primary business divisions: Diagnosis & Treatment, Connected Care, and Personal Health. Within its Diagnosis & Treatment segment, Philips delivers advanced diagnostic imaging solutions, which include magnetic resonance imaging (MRI), computed tomography (CT) systems, X-ray apparatus, and spectral CT technology based on detector platforms. This division also provides molecular and hybrid imaging capabilities crucial for nuclear medicine. Furthermore, it offers integrated systems for interventional procedures, along with ultrasound (echography) solutions specifically designed for diagnosis, treatment planning, and guidance in fields such as cardiology, general imaging, obstetrics/gynecology, and point-of-care applications. Complementing these are proprietary software tools for diagnostic and interventional support, alongside comprehensive enterprise diagnostic informatics products and associated services. The Connected Care division focuses on providing solutions for acute patient management, emergency care services, and specialized offerings for sleep and respiratory conditions. This also encompasses electronic medical record (EMR) systems and broader care management platforms. Meanwhile, the Personal Health segment caters to consumer well-being with products such as electric toothbrushes, replacement brush heads, interdental cleaning aids, and teeth whitening kits. It also manufactures infant feeding products and digital parental support tools, in addition to a range of male grooming and beauty products. Philips has forged significant strategic alliances, notably a collaboration with Ibex Medical Analytics Ltd. This partnership aims to jointly promote digital pathology and AI-driven solutions to hospitals, healthcare networks, and pathology laboratories worldwide. The company also maintains a key partnership agreement with NICO.LAB. Established in 1891, the company was initially known as Koninklijke Philips Electronics N.V. before officially rebranding as Koninklijke Philips N.V. in May 2013. Its corporate headquarters are located in Amsterdam, the Netherlands.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/EBITDA,
Target Price
The average target price of PHG is 32 and suggests 22% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase